(Courtesy: BSIP VEM/Science Photo Library) 
Researchers from the Genetics and Public Policy Center at Johns Hopkins University are suggesting some companies are using misleading claims to push tests that have limited clinical validation — something they say may ultimately hurt the pharmacogenetics field.  They recommend that this type of testing needs more oversight and are calling for more regulation of the pharmacogenetic testing industry.  For example, they noted, the US Food and Drug Administration doesn’t regulate most laboratory-developed tests, though clinical laboratories are certified under the Clinical Laboratory Improvement Amendment (CLIA).
In particular, they focused on tests for genetic variants in CYP450 …read more